reports
Malin Corporation: 3 directors
Three Directors at Malin Corporation sold 61,818 shares at 9.300EUR. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- Liberum Research Team
- Edward Thomason
- Seb Jantet
LIBERUM: Malin Corporation* - Prelims & tender offer price at premium
Malin has released 2022 prelims and priced the previously announced €140m tender offer at a 25% premium to the current share price. Despite a difficult biotech equity market last year, Malin performed exceptionally well in 2022 and has delivered on its strategy of crystallising value from its portfolio and returning capital to shareholders. After the tender offer, the company is left with €33m of cash, more than enough to realise further value from the portfolio and to deploy in new opportunitie...
Malin Corporation plc appoints Dr. Andrew von Eschenbach, former FDA c...
DUBLIN--(BUSINESS WIRE)-- Malin Corporation plc. (ISE:MLC, "Malin"), an Irish-based global life sciences company, today announced the appointment of Dr. Andrew von Eschenbach as Chief Medical Adviser, effective immediately. Dr. von Eschenbach previously served as an advisory partner to Malin. Dr. von Eschenbach is currently the president of Samaritan Health Initiatives Inc, and serves as an adjunct professor at Houston’s University of Texas MD Anderson Cancer center. He is also a member of the Prostate Cancer Foundation Board...
Malin Announces U.S. FDA Approval for New Hourglassâ„¢ Peripheral Embo...
DUBLIN--(BUSINESS WIRE)-- Malin Corporation plc. (ISE:MLC, "Malin"), an Irish based and globally operating life sciences company, today announced that its EMBA device, known as the Hourglass™ Peripheral Embolisation Plug, was granted U.S. FDA 510(k) clearance to commence marketing in the US. The Hourglass™ peripheral embolisation plug represents a breakthrough in peripheral embolisation devices in that it is designed to provide precise, secure, over-the-wire delivery and immediate occlusion with a single integrated device. ...
Malin Investee Company - Melinta Therapeutics - To Be Transformed into...
DUBLIN--(BUSINESS WIRE)-- Malin Corporation plc. (ISE:MLC, "Malin"), an Irish based and globally operating life sciences company, today announced that Melinta Therapeutics, Inc. (“Melinta”), a Malin investee company focused on discovering, developing, and commercialising novel antibiotics to treat serious bacterial infections, has entered into a definitive agreement with Cempra, Inc. (Nasdaq:CEMP, “Cempra”), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settin...
Malin Makes Significant Commitment to Artizan Biosciences, Inc.
DUBLIN--(BUSINESS WIRE)-- Malin Corporation plc. ("Malin"), an Irish based and globally operating life sciences company, today announced that it has acquired a 32% shareholding of Artizan Biosciences, Inc. (“Artizan”). Malin invested in a founding equity round alongside Hatteras Venture Partners, a venture capital firm with which Malin has a strategic partnership. Artizan is a newly created biotechnology company headquartered in Durham, NC, with labs in New Haven, CT, that was founded to address diseases involving the human i...
Malin Announces Investment in Wren Therapeutics Ltd.
DUBLIN--(BUSINESS WIRE)-- Malin Corporation plc. ("Malin"), an Irish based and globally operating life sciences company, today announced that it has acquired a 33% shareholding of Wren Therapeutics Limited (“Wren”). Wren is a newly created biopharmaceutical company based in Cambridge, UK with a focus on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Wren was spun out of the University of Cambridge, UK, and Lund University, Sweden and was formally founded as a bus...
Malin Announces Investment in Cilatus BioPharma AG
DUBLIN--(BUSINESS WIRE)-- Malin Corporation plc. (ISE:MLC, "Malin"), an Irish-based and globally operating life sciences company, today announced that it has acquired an 80% shareholding of Cilatus BioPharma AG (“Cilatus”). Cilatus was founded by Dr. Johannes Roebers and focuses on strategic and operational consulting services in CMC/Technical Development, GMP Manufacturing, Regulatory Affairs, Quality Control/Assurance, Supply Chain, Engineering, Validation and Qualification for small and large molecules. The company is domi...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Malin Corporation plc appoints Peter Schwartzman to Senior Management ...
Dublin--(BUSINESS WIRE)-- Malin Corporation plc. (ISE:MLC, "Malin"), an Irish-based global life sciences company, today announced the appointment of Peter Schwartzman to the company’s senior team, effective immediately. Peter Schwartzman brings 30 years of experience in asset and risk management to Malin. He was most recently a Managing Director in the Leveraged Finance Group within BlackRock Financial Management - the world’s largest asset manager. From 1998 to 2016, Peter was a leading member of a team that managed over $40...
Malin Business Advancement As A Result of Novan IPO
DUBLIN--(BUSINESS WIRE)-- A Malin Corporation plc (ISE:MLC,“Malin”) investee company, Novan Inc. ("Novan"), today successfully completed an initial public offering (“IPO”) of its shares. Novan raised at least $45 million and will trade on the NASDAQ Global Market under the ticker symbol NOVN. In December 2015, Novan’s non-dermatological assets were separated from its broad nitric oxide platform into KNOW Bio, LLC (“KNOW Bio”). The shares of this company were distributed to shareholders. The remaining company, Novan, (which co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.